Want to see ES:PHM full AI Analyst Report?
PHM Stock Chart & Stats
€97.35
€0.65(0.83%)
At close: 4:00 PM EST
€97.35
€0.65(0.83%)
Day’s Range― - ―
52-Week Range€64.00 - €105.20
Previous CloseN/A
Volume4.24K
Average Volume (3M)74.16K
Market Cap
€1.34B
Enterprise Value€1.19B
Total Cash (Recent Filing)€167.85M
Total Debt (Recent Filing)€47.54M
Price to Earnings (P/E)16.2
Beta0.71
Next Earnings
Jul 29, 2026EPS Estimate
0.18Next Dividend Ex-DateN/A
Dividend Yield1.04%
Share Statistics
EPS (TTM)4.65
Shares Outstanding18,000,000
10 Day Avg. Volume71,270
30 Day Avg. Volume74,161
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)5.12
Price to Sales (P/S)5.82
P/FCF Ratio29.46
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€110.50Price Target Upside13.51% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)2.14
Revenue Forecast (FY)€212.49M
Bulls Say, Bears Say
Bulls Say
High Margins And ProfitabilitySustained high gross and net margins provide a durable earnings buffer and support internal funding for R&D and commercialization. The step-up in operating profit versus 2024–2025 indicates the business can generate strong operating leverage from its product mix, enhancing long-term cash flow potential and reinvestment capacity.
Improved Cash GenerationMaterial positive operating and free cash flow on a trailing basis reduces reliance on external financing and supports ongoing trials, commercialization and partnerships. With TTM free cash flow around 85% of net income, the company shows the ability to convert earnings into durable liquidity that can fund strategic initiatives.
Conservative Leverage And Stronger EquityLow debt relative to equity provides long-term financial flexibility and lower fixed interest burden, enabling the firm to endure clinical or commercial setbacks. Equity growth versus 2023–2024 and recent strong ROE (TTM ~35.7%) support capacity to invest in the pipeline without immediate refinancing pressure.
Bears Say
Earnings And Revenue VolatilityHistorical swings in revenue and profits create persistent forecasting and planning challenges, limiting visibility for capital allocation. This cyclicality means recent strong margins and growth may not be steady, raising execution risk for sustaining commercial momentum and for timing of partner milestones or launches.
Inconsistent Cash Conversion HistoryPast periods of weak or negative free cash flow show earnings have not consistently translated to cash, which can force financing or constrain R&D spend during downturns. Even with recent improvement, uneven cash conversion is a durable operational risk affecting liquidity planning and resilience through cycles.
Dependence On Clinical, Regulatory And Partner MilestonesRevenue and milestone timing are structurally tied to binary development and regulatory outcomes and partner payment schedules. This dependency produces lumpy revenue streams and exposes the company to outsized event risk, which can materially alter cash flow and commercialization plans over the medium term.
Pharma Mar SA News
PHM FAQ
What was Pharma Mar SA’s price range in the past 12 months?
Pharma Mar SA lowest stock price was €64.00 and its highest was €105.20 in the past 12 months.
What is Pharma Mar SA’s market cap?
Pharma Mar SA’s market cap is €1.34B.
When is Pharma Mar SA’s upcoming earnings report date?
Pharma Mar SA’s upcoming earnings report date is Jul 29, 2026 which is in 28 days.
How were Pharma Mar SA’s earnings last quarter?
Pharma Mar SA released its earnings results on Apr 23, 2026. The company reported €0.088 earnings per share for the quarter, beating the consensus estimate of €0.008 by €0.08.
Is Pharma Mar SA overvalued?
According to Wall Street analysts Pharma Mar SA’s price is currently Undervalued.
Does Pharma Mar SA pay dividends?
Pharma Mar SA pays a Annually dividend of €0.8 which represents an annual dividend yield of 1.04%. See more information on Pharma Mar SA dividends here
What is Pharma Mar SA’s EPS estimate?
Pharma Mar SA’s EPS estimate is 0.18.
How many shares outstanding does Pharma Mar SA have?
Pharma Mar SA has 18,000,000 shares outstanding.
What happened to Pharma Mar SA’s price movement after its last earnings report?
Pharma Mar SA reported an EPS of €0.088 in its last earnings report, beating expectations of €0.008. Following the earnings report the stock price went up 3.083%.
Which hedge fund is a major shareholder of Pharma Mar SA?
Currently, no hedge funds are holding shares in ES:PHM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Pharma Mar SA Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€110.50 (13.51% Upside)
€110.50 (13.51% Upside)
Insider Transactions
Bought Shares
Worth €132.0K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
27.08%
12-Months-Change
Fundamentals
Return on Equity
35.74%
Trailing 12-Months
Asset Growth
23.22%
Trailing 12-Months
Company Description
Pharma Mar SA
Pharma Mar, S.A., a biopharmaceutical firm established in 1986 and headquartered in Madrid, Spain, is dedicated to the research, development, production, and global sale of marine-derived bioactive compounds. Its primary focus is oncology, with operations spanning Spain, Italy, Germany, Ireland, the wider European Union, the United States, and other international markets. The company's activities are organized into three key segments: Oncology, Diagnostics, and RNA interference. Among its developed and commercialized treatments are Yondelis, prescribed for soft tissue sarcomas and ovarian cancer; Aplidin, targeting multiple myeloma; and Zepzelca, used for patients with small cell lung cancer. Furthermore, Pharma Mar is advancing PM14, currently in Phase II clinical trials for various solid tumors. Beyond pharmaceuticals, the company manufactures and markets diagnostic kits and is involved in creating therapeutic drugs designed to reduce or silence gene expression.
PHM Company Deck
PHM Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated a strong set of financial results and clear strategic progress—notably robust revenue growth (+27% y/y), a material improvement in profitability (EBITDA ~5x; net income +187%), healthy cash generation (EUR 53m) and multiple regulatory/commercial advances for Zepzelca and other assets. Pipeline momentum (LAGOON, SaLuDo, PM54, PM534) and licensing deals (e.g., Merck for Japan) provide additional upside. Offsetting factors include a 12% decline in U.S. Zepzelca royalties driven by FX and competition, outstanding pricing/reimbursement negotiations in Europe, exposure to partner-controlled disclosures, generics risk for Yondelis, and planned increases in commercial spending. Overall, positive operational and financial trends materially outweigh the identified risks, though execution on European launches and partner dynamics will be key to sustaining momentum.View all ES:PHM earnings summariesPHM Stock 12 Month Forecast
Average Price Target
€110.50
▲(13.51% Upside)
Technical Analysis
Laboratorios Farmaceuticos Rovi
―
Oryzon Genomics SA
―
―
1nKemia IUCT Group SA
―
Atrys Health SA
―
Options Prices
Currently, No data available
---